在HIV门诊研究（HOPS）队列中，接受替诺福韦与利托那韦/洛匹那韦或利托那韦/阿扎那韦联合治疗的患者的肾功能 - Suppr

Suppr

超能文献

Renal function in patients receiving tenofovir with ritonavir/lopinavir or ritonavir/atazanavir in the HIV Outpatient Study (HOPS) cohort.

作者信息

Buchacz Kate, Young Benjamin, Baker Rose K, Moorman Anne, Chmiel Joan S, Wood Kathy C, Brooks John T

出版信息

J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):626-8. doi: 10.1097/01.qai.0000242461.35768.45.

DOI:10.1097/01.qai.0000242461.35768.45

PMID:17133215

Abstract

摘要

相似文献

Renal function in patients receiving tenofovir with ritonavir/lopinavir or ritonavir/atazanavir in the HIV Outpatient Study (HOPS) cohort.

J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):626-8. doi: 10.1097/01.qai.0000242461.35768.45.

Urolithiasis under atazanavir boosted and tenofovir therapy: a case report.

J Chemother. 2008 Feb;20(1):143-4. doi: 10.1179/joc.2008.20.1.143.

Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.

J Acquir Immune Defic Syndr. 2010 Mar;53(3):323-32. doi: 10.1097/QAI.0b013e3181c990bf.

[Atazanavir-induced nephrolithiasis].

Enferm Infecc Microbiol Clin. 2009 Feb;27(2):134-5. doi: 10.1016/j.eimc.2007.12.001. Epub 2009 Feb 25.

Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study.

J Antimicrob Chemother. 2011 Feb;66(2):363-70. doi: 10.1093/jac/dkq457. Epub 2010 Dec 9.

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.

Lancet. 2008 Aug 23;372(9639):646-55. doi: 10.1016/S0140-6736(08)61081-8.

The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.

Expert Rev Anti Infect Ther. 2009 Sep;7(7):801-5. doi: 10.1586/eri.09.66.

Evaluation of renal adverse effects of combination anti-retroviral therapy including tenofovir in HIV-infected patients.

J Pharm Pharm Sci. 2013;16(3):405-13. doi: 10.18433/j32p5c.

Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.

Clin Drug Investig. 2007;27(1):67-74. doi: 10.2165/00044011-200727010-00006.

Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States.

J Med Econ. 2011;14(2):167-78. doi: 10.3111/13696998.2011.554932. Epub 2011 Feb 2.

引用本文的文献

Comparison of Renal Function Biomarkers of Serum Creatinine and Cystatin C in HIV-Infected People on Dolutegravir-Containing Therapy.

Infect Drug Resist. 2022 Apr 8;15:1695-1706. doi: 10.2147/IDR.S347054. eCollection 2022.

Kidney Disease in HIV Infection.

J Clin Med. 2019 Aug 19;8(8):1254. doi: 10.3390/jcm8081254.

Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapine.

AIDS. 2014 May 15;28(8):1135-42. doi: 10.1097/QAD.0000000000000202.

A review of cardiovascular and renal function monitoring: a consideration of older adults with HIV.

HIV AIDS (Auckl). 2013 Sep 16;5:263-74. doi: 10.2147/HIV.S36311.

Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?

J Am Soc Nephrol. 2013 Oct;24(10):1519-27. doi: 10.1681/ASN.2012080857. Epub 2013 Sep 19.

Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study.

BMC Infect Dis. 2013 Jul 1;13:301. doi: 10.1186/1471-2334-13-301.

Tenofovir-associated renal dysfunction in clinical practice: An observational cohort from western India.

Indian J Sex Transm Dis AIDS. 2010 Jan;31(1):30-4. doi: 10.4103/0253-7184.68998.

Tenofovir nephrotoxicity: 2011 update.

AIDS Res Treat. 2011;2011:354908. doi: 10.1155/2011/354908. Epub 2011 Jun 7.

Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.

Ann Intern Med. 2011 Apr 5;154(7):445-56. doi: 10.7326/0003-4819-154-7-201104050-00316. Epub 2011 Feb 14.

The nephrotoxic effects of HAART.

Nat Rev Nephrol. 2009 Oct;5(10):563-73. doi: 10.1038/nrneph.2009.142.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Renal function in patients receiving tenofovir with ritonavir/lopinavir or ritonavir/atazanavir in the HIV Outpatient Study (HOPS) cohort.

作者信息

Buchacz Kate, Young Benjamin, Baker Rose K, Moorman Anne, Chmiel Joan S, Wood Kathy C, Brooks John T

出版信息

J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):626-8. doi: 10.1097/01.qai.0000242461.35768.45.

DOI:10.1097/01.qai.0000242461.35768.45

PMID:17133215

Abstract

摘要

相似文献

Renal function in patients receiving tenofovir with ritonavir/lopinavir or ritonavir/atazanavir in the HIV Outpatient Study (HOPS) cohort.

J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):626-8. doi: 10.1097/01.qai.0000242461.35768.45.

Urolithiasis under atazanavir boosted and tenofovir therapy: a case report.

J Chemother. 2008 Feb;20(1):143-4. doi: 10.1179/joc.2008.20.1.143.

J Acquir Immune Defic Syndr. 2010 Mar;53(3):323-32. doi: 10.1097/QAI.0b013e3181c990bf.

[Atazanavir-induced nephrolithiasis].

Enferm Infecc Microbiol Clin. 2009 Feb;27(2):134-5. doi: 10.1016/j.eimc.2007.12.001. Epub 2009 Feb 25.

Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study.

J Antimicrob Chemother. 2011 Feb;66(2):363-70. doi: 10.1093/jac/dkq457. Epub 2010 Dec 9.

Lancet. 2008 Aug 23;372(9639):646-55. doi: 10.1016/S0140-6736(08)61081-8.

The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.

Expert Rev Anti Infect Ther. 2009 Sep;7(7):801-5. doi: 10.1586/eri.09.66.

Evaluation of renal adverse effects of combination anti-retroviral therapy including tenofovir in HIV-infected patients.

J Pharm Pharm Sci. 2013;16(3):405-13. doi: 10.18433/j32p5c.

Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.

Clin Drug Investig. 2007;27(1):67-74. doi: 10.2165/00044011-200727010-00006.

Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States.

J Med Econ. 2011;14(2):167-78. doi: 10.3111/13696998.2011.554932. Epub 2011 Feb 2.

引用本文的文献

Comparison of Renal Function Biomarkers of Serum Creatinine and Cystatin C in HIV-Infected People on Dolutegravir-Containing Therapy.

Infect Drug Resist. 2022 Apr 8;15:1695-1706. doi: 10.2147/IDR.S347054. eCollection 2022.

Kidney Disease in HIV Infection.

J Clin Med. 2019 Aug 19;8(8):1254. doi: 10.3390/jcm8081254.

Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapine.

AIDS. 2014 May 15;28(8):1135-42. doi: 10.1097/QAD.0000000000000202.

A review of cardiovascular and renal function monitoring: a consideration of older adults with HIV.

HIV AIDS (Auckl). 2013 Sep 16;5:263-74. doi: 10.2147/HIV.S36311.

Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?

J Am Soc Nephrol. 2013 Oct;24(10):1519-27. doi: 10.1681/ASN.2012080857. Epub 2013 Sep 19.

Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study.

BMC Infect Dis. 2013 Jul 1;13:301. doi: 10.1186/1471-2334-13-301.

Tenofovir-associated renal dysfunction in clinical practice: An observational cohort from western India.

Indian J Sex Transm Dis AIDS. 2010 Jan;31(1):30-4. doi: 10.4103/0253-7184.68998.

Tenofovir nephrotoxicity: 2011 update.

AIDS Res Treat. 2011;2011:354908. doi: 10.1155/2011/354908. Epub 2011 Jun 7.

Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.

Ann Intern Med. 2011 Apr 5;154(7):445-56. doi: 10.7326/0003-4819-154-7-201104050-00316. Epub 2011 Feb 14.

The nephrotoxic effects of HAART.

Nat Rev Nephrol. 2009 Oct;5(10):563-73. doi: 10.1038/nrneph.2009.142.